Ibrutinib therapy for lymphoplasmacytic lymphoma

Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation.

Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation Jorge J. Castillo, Irene M. Ghobrial & Steven P. Treon To cite this article: Jorge J. Castillo, Irene M. Ghobrial & Steven P. Treon (2016) Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation, Leukemia & Lymphoma, 57:11, 2699-2701...

Waldenstrom's macrogloblinemia/ lymphoplasmacytic lymphoma.

Waldenström’s macroglobulinemia (WM) is a distinct clinicopathological entity resulting from the accumulation, predominantly in the bone marrow, of clonally related lymphocytes, lymphoplasmacytic cells and plasma cells which secrete a monoclonal IgM protein (Figure 1). This condition is considered to correspond to the lymphoplasmacytic lymphoma (LPL) as defined by the Revised European American ...

PRDM1 expression levels in marginal zone lymphoma and lymphoplasmacytic lymphoma

PRDM1 (BLIMP1) is a transcription repressor protein shown to be involved in B-cell differentiation into plasma cells. Marginal zone lymphomas (MZL) and lymphoplasmacytic lymphomas (LPL) are B cell lymphomas that both show some degree of plasmacytic differentiation and thus can sometimes constitute a difficult differential diagnosis. In this study, we investigated if MZL and LPL have abnormaliti...

Lymphoplasmacytic lymphoma presenting as retinal hemorrhage.

Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.

We retrospectively reviewed the immunophenotypic profile of 75 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) analyzed by flow cytometry. All patients had monoclonal IgM (median, 2,100 mg/dL [21 g/L]) in serum and were considered clinically to have WM. The neoplastic cells, in all cases, expressed monoclonal immunoglobulin light chain (k, 55; l, 20) and CD19, and eve...